Article Cited by others


Off-label use of medicine: Perspective of physicians, patients, pharmaceutical companies and regulatory authorities

Gupta Sandeep Kumar, Nayak Roopa Prasad

Year : 2014| Volume: 5| Issue : 2 | Page no: 88-92

   This article has been cited by
1 Potential harm caused by physicians' a-priori beliefs in the clinical effectiveness of hydroxychloroquine and its impact on clinical and economic outcome – A simulation approach
Claudia Ebm, Fabio Carfagna, Sarah Edwards, Alberto Mantovani, Maurizio Cecconi
Journal of Critical Care. 2021; 62: 138
[Pubmed]  [Google Scholar] [DOI]
2 Off-label use of antipsychotic medications in psychiatric inpatients in China: a national real-world survey
Juan Wang, Feng Jiang, Yating Yang, Yulong Zhang, Zhiwei Liu, Xiaorong Qin, Xueqin Tao, Tingfang Liu, Yuanli Liu, Yi-lang Tang, Huanzhong Liu, Robert O. Cotes
BMC Psychiatry. 2021; 21(1)
[Pubmed]  [Google Scholar] [DOI]
3 Impact of a health alert and its implementation on flutamide prescriptions for women: an interrupted time series analysis
Raquel Vázquez-Mourelle, Eduardo Carracedo-Martínez, Adolfo Figueiras
BMC Health Services Research. 2020; 20(1)
[Pubmed]  [Google Scholar] [DOI]
4 Unburdening dementia – a basic social process grounded theory based on a primary care physician survey from 25 countries
Ferdinando Petrazzuoli, Shlomo Vinker, Sebastian Palmqvist, Patrik Midlöv, Jan De Lepeleire, Alessandro Pirani, Thomas Frese, Nicola Buono, Jette Ahrensberg, Radost Asenova, Quintí Foguet Boreu, Gülsen Ceyhun Peker, Claire Collins, Miro Hanževacki, Kathryn Hoffmann, Claudia Iftode, Tuomas H. Koskela, Donata Kurpas, Jean Yves Le Reste, Bjørn Lichtwarck, Davorina Petek, Diego Schrans, Jean Karl Soler, Sven Streit, Athina Tatsioni, Péter Torzsa, Pemra C. Unalan, Harm van Marwijk, Hans Thulesius
Scandinavian Journal of Primary Health Care. 2020; 38(3): 253
[Pubmed]  [Google Scholar] [DOI]
5 The Effect of RCTs on Demand for Off-Label Cancer Drugs
Rebecca Jay McKibbin
SSRN Electronic Journal. 2020;
[Pubmed]  [Google Scholar] [DOI]
6 Has Drug Repurposing Fulfilled Its Promise in Acute Myeloid Leukaemia?
Debora Valli, Alicja M. Gruszka, Myriam Alcalay
Journal of Clinical Medicine. 2020; 9(6): 1892
[Pubmed]  [Google Scholar] [DOI]
7 Biologics in dermatology: Off-label indications
Debdeep Mitra, Ajay Chopra, Neerja Saraswat, Barnali Mitra, Krishna Talukdar, Reetu Agarwal
Indian Dermatology Online Journal. 2020; 11(3): 319
[Pubmed]  [Google Scholar] [DOI]
8 Knowledge and attitudes of patients in primary care on off-label treatment
Mario Curkovic,Dražen Gorjanski
International Journal of Risk & Safety in Medicine. 2018; : 1
[Pubmed]  [Google Scholar] [DOI]
9 Identifying Off-Label Prescriptions Through Data Mining in Danish Community Pharmacy Servers: An Exploratory Study on Desmopressin, Diclofenac, Fucidin, Mirtazapine and Quetiapine
Monika Andrulyte,Ole Jannik Bjerrum
Basic & Clinical Pharmacology & Toxicology. 2018;
[Pubmed]  [Google Scholar] [DOI]
10 Practice-Based Research Networks and the Mandate for Real-World Evidence
Elizabeth Hall-Lipsy, Leila Barraza, Christopher Robertson
American Journal of Law & Medicine. 2018; 44(2-3): 219
[Pubmed]  [Google Scholar] [DOI]
11 Extended infusion—putting the benefit into context
Markus Zeitlinger
The Lancet Infectious Diseases. 2018; 18(4): 380
[Pubmed]  [Google Scholar] [DOI]
12 Drug repositioning, a new alternative in infectious diseases
Marissa Bolson Serafin,Rosmari Hörner
The Brazilian Journal of Infectious Diseases. 2018; 22(3): 252
[Pubmed]  [Google Scholar] [DOI]
13 Repurposing N,Næ-bis-(arylamidino)-1,4-piperazinedicarboxamidines: An unexpected class of potent inhibitors of cholinesterases
Anne Loesche,Jana Wiese,Sven Sommerwerk,Vivienne Simon,Wolfgang Brandt,René Csuk
European Journal of Medicinal Chemistry. 2017; 125: 430
[Pubmed]  [Google Scholar] [DOI]
14 PMTDS: a computational method based on genetic interaction networks for Precision Medicine Target-Drug Selection in cancer
Varshini Vasudevaraja,Jamie Renbarger,Ridhhi Girish Shah,Garrett Kinnebrew,Murray Korc,Limei Wang,Yang Huo,Enze Liu,Lang Li,Lijun Cheng
Quantitative Biology. 2017;
[Pubmed]  [Google Scholar] [DOI]
15 Repurposing Drugs in Oncology: Next Steps
Ciska Verbaanderd,Lydie Meheus,Isabelle Huys,Pan Pantziarka
Trends in Cancer. 2017;
[Pubmed]  [Google Scholar] [DOI]
16 Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act Coverage
Aaron S. Kesselheim,Carolyn L. Treasure,Steven Joffe
PLOS Medicine. 2017; 14(1): e1002190
[Pubmed]  [Google Scholar] [DOI]
17 Off-label use of medicines: The need for good practice guidelines
Marc Dooms,James Killick
International Journal of Risk & Safety in Medicine. 2017; 29(1-2): 17
[Pubmed]  [Google Scholar] [DOI]
18 Off-label use of orphan medicinal products: a Belgian qualitative study
Marc Dooms,David Cassiman,Steven Simoens
Orphanet Journal of Rare Diseases. 2016; 11(1)
[Pubmed]  [Google Scholar] [DOI]
19 After Amarin v FDA: What Will the Future Hold for Off-label Promotion Regulation?
Tim K. Mackey,Bryan A. Liang
Mayo Clinic Proceedings. 2016;
[Pubmed]  [Google Scholar] [DOI]
20 Drotaverine - a Concealed Cytostatic!
Ioana Z. Pavel,Lucie Heller,Sven Sommerwerk,Anne Loesche,Ahmed Al-Harrasi,René Csuk
Archiv der Pharmazie. 2016;
[Pubmed]  [Google Scholar] [DOI]
21 Prescribing practice and off-label use of psychotropic medications in post-acute brain injury rehabilitation centres: A cross-sectional survey
Federica Edith Pisa,Giorgia Cosano,Manuela Giangreco,Tullio Giorgini,Emanuele Biasutti,Fabio Barbone
Brain Injury. 2015; 29(4): 508
[Pubmed]  [Google Scholar] [DOI]


Read this article